1.A case of limbic encephalitis with positive antibody to the GABAB receptor.
Yan ZHANG ; Ying-Ying SU ; Yuan GAO
Chinese Medical Journal 2013;126(18):3599-3600
2.Progress in studies on the role of gamma-aminobutyric acid.
Chinese Medical Journal 2012;125(7):1322-1330
3.Effect of Sildenafil on Neuropathic Pain and Hemodynamics in Rats.
Lan Ji HUANG ; Myung Ha YOON ; Jeong Il CHOI ; Woong Mo KIM ; Hyung Gon LEE ; Yeo Ok KIM
Yonsei Medical Journal 2010;51(1):82-87
PURPOSE: The inhibition of phosphodiesterase 5 produces an antinociception through the increase of cyclic guanosine monophosphate (cGMP), and increasing cGMP levels enhance the release of gamma-aminobutyric acid (GABA). Furthermore, this phosphodiesterase 5 plays a pivotal role in the regulation of the vasodilatation associated to cGMP. In this work, we examined the contribution of GABA receptors to the effect of sildenafil, a phosphodiesterase 5 inhibitor, in a neuropathic pain rat, and assessed the hemodynamic effect of sildenafil in normal rats. MATERIALS AND METHODS: Neuropathic pain was induced by ligation of L5/6 spinal nerves in Sprague-Dawley male rats. After observing the effect of intravenous sildenafil on neuropathic pain, GABAA receptor antagonist (bicuculline) and GABAB receptor antagonist (saclofen) were administered prior to delivery of sildenafil to determine the role of GABA receptors in the activity of sildenafil. For hemodynamic measurements, catheters were inserted into the tail artery. Mean arterial pressure (MAP) and heart rate (HR) were measured over 60 min following administration of sildenafil. RESULTS: Intravenous sildenafil dose-dependently increased the withdrawal threshold to the von Frey filament application in the ligated paw. Intravenous bicuculline and saclofen reversed the antinociception of sildenafil. Intravenous sildenafil increased the magnitude of MAP reduction at the maximal dosage, but it did not affect HR response. CONCLUSION: These results suggest that sildenafil is active in causing neuropathic pain. Both GABAA and GABAB receptors are involved in the antinociceptive effect of sildenafil. Additionally, intravenous sildenafil reduces MAP without affecting HR.
Animals
;
Baclofen/analogs & derivatives/pharmacology
;
Bicuculline/pharmacology
;
Blood Pressure/drug effects
;
Dose-Response Relationship, Drug
;
Heart Rate/drug effects
;
Hemodynamics/drug effects
;
Male
;
Neuralgia/*drug therapy
;
Pain Threshold/drug effects
;
Phosphodiesterase Inhibitors/*therapeutic use
;
Piperazines/*therapeutic use
;
Purines/therapeutic use
;
Rats
;
Rats, Sprague-Dawley
;
Receptors, GABA-A/antagonists & inhibitors/physiology
;
Receptors, GABA-B/antagonists & inhibitors/physiology
;
Sulfones/*therapeutic use
4.Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of FLT3-ITD/DNMT3A R882 Double-Mutated Acute Myeloid Leukemia.
Shan-Hao TANG ; Ying LU ; Pi-Sheng ZHANG ; Dong CHEN ; Xu-Hui LIU ; Xiao-Hong DU ; Jun-Jie CAO ; Shuang-Yue LI ; Ke-Ya SHA ; Lie-Guang CHEN ; Xian-Xu ZHUANG ; Pei-Pei YE ; Li LIN ; Ren-Zhi PEI
Journal of Experimental Hematology 2023;31(1):45-49
OBJECTIVE:
To observe the clinical significance of translocator proteins (TSPO) gene in the treatment of FLT3-ITD/DNMT3A R882 double-mutated acute myeloid leukemia (AML).
METHODS:
Seventy-six patients with AML hospitalized in the Department of Hematology of the Affiliated People's Hospital of Ningbo University from June 2018 to June 2020 were selected, including 34 patients with FLT3-ITD mutation, 27 patients with DNMT3A R882 mutation, 15 patients with FLT3-ITD/DNMT3A R882 double mutation, as well as 19 patients with immune thrombocytopenia (ITP) hospitalized during the same period as control group. RNA was routinely extracted from 3 ml bone marrow retained during bone puncture, and TSPO gene expression was detected by transcriptome sequencing (using 2-deltadeltaCt calculation).
RESULTS:
The expression of TSPO gene in FLT3-ITD group and DNMT3A R882 group at first diagnosis was 2.02±1.04 and 1.85±0.76, respectively, which were both higher than 1.00±0.06 in control group, but the differences were not statistically significant (P=0.671, P=0.821). The expression of TSPO gene in the FLT3-ITD/DNMT3A R882 group was 3.98±1.07, wich was significantly higher than that in the FLT3-ITD group and DNMT3A R882 group, the differences were statistically significant (P=0.032, P=0.021). The expression of TSPO gene in patients who achieved complete response after chemotherapy in the FLT3-ITD/DNMT3A R882 group was 1.19±0.87, which was significantly lower than that at first diagnosis, and the difference was statistically significant (P=0.011).
CONCLUSION
TSPO gene may be used as an indicator of efficacy in FLT3-ITD /DNMT3A R882 double-mutated AML.
Humans
;
DNA (Cytosine-5-)-Methyltransferases/genetics*
;
DNA Methyltransferase 3A
;
Mutation
;
Leukemia, Myeloid, Acute/drug therapy*
;
Nucleophosmin
;
Prognosis
;
fms-Like Tyrosine Kinase 3/genetics*
;
Receptors, GABA/therapeutic use*
5.Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor.
Tao ZHU ; Wei ZHANG ; Dao-xin WANG ; Ni-wen HUANG ; Hong BO ; Wang DENG ; Jia DENG
Chinese Medical Journal 2012;125(8):1457-1464
BACKGROUNDAsthma is a chronic inflammatory disease characterized by reversible bronchial constriction, pulmonary inflammation and airway remodeling. Current standard therapies for asthma provide symptomatic control, but fail to target the underlying disease pathology. Furthermore, no therapeutic agent is effective in preventing airway remodeling. A substantial amount of evidence suggests that statins have anti-inflammatory properties and immunomodulatory activity. In this study, we investigated the effect of rosuvastatin on airway inflammation and its inhibitory mechanism in mucus hypersecretion in a murine model of chronic asthma.
METHODSBALB/c mice were sensitized and challenged by ovalbumin to induce asthma. The recruitment of inflammatory cells into bronchoalveolar lavage fluid (BALF) and the lung tissues were measured by Diff-Quik staining and hematoxylin and eosin (H&E) staining. ELISA was used for measuring the levels of IL-4, IL-5, IL-13 and TNF-α in BALF. Periodic acid-Schiff (PAS) staining was used for mucus secretion. Gamma-aminobutyric acid type A receptor (GABAAR) β2 expression was measured by means of immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting.
RESULTSRosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-α in BALF, along with the histological mucus index (HMI) and GABAAR β2 expression. Changes occurred in a dose-dependent manner.
CONCLUSIONSBased on its ability to reduce the inflammatory response and mucus hypersecretion by regulating GABAAR activity in a murine model of chronic asthma, rosuvastatin may be a useful therapeutic agent for treatment of asthma.
Animals ; Asthma ; drug therapy ; metabolism ; Chronic Disease ; Disease Models, Animal ; Female ; Fluorobenzenes ; pharmacology ; therapeutic use ; GABA-A Receptor Antagonists ; pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; pharmacology ; Lung ; chemistry ; Mice ; Mice, Inbred BALB C ; Mucus ; secretion ; Pyrimidines ; pharmacology ; therapeutic use ; Receptors, GABA-A ; analysis ; Rosuvastatin Calcium ; Sulfonamides ; pharmacology ; therapeutic use
6.GABA Receptor Activity Suppresses the Transition from Inter-ictal to Ictal Epileptiform Discharges in Juvenile Mouse Hippocampus.
Yan-Yan CHANG ; Xin-Wei GONG ; Hai-Qing GONG ; Pei-Ji LIANG ; Pu-Ming ZHANG ; Qin-Chi LU
Neuroscience Bulletin 2018;34(6):1007-1016
Exploring the transition from inter-ictal to ictal epileptiform discharges (IDs) and how GABA receptor-mediated action affects the onset of IDs will enrich our understanding of epileptogenesis and epilepsy treatment. We used Mg-free artificial cerebrospinal fluid (ACSF) to induce epileptiform discharges in juvenile mouse hippocampal slices and used a micro-electrode array to record the discharges. After the slices were exposed to Mg-free ACSF for 10 min-20 min, synchronous recurrent seizure-like events were recorded across the slices, and each event evolved from inter-ictal epileptiform discharges (IIDs) to pre-ictal epileptiform discharges (PIDs), and then to IDs. During the transition from IIDs to PIDs, the duration of discharges increased and the inter-discharge interval decreased. After adding 3 μmol/L of the GABA receptor agonist muscimol, PIDs and IDs disappeared, and IIDs remained. Further, the application of 10 μmol/L muscimol abolished all the epileptiform discharges. When the GABA receptor antagonist bicuculline was applied at 10 μmol/L, IIDs and PIDs disappeared, and IDs remained at decreased intervals. These results indicated that there are dynamic changes in the hippocampal network preceding the onset of IDs, and GABA receptor activity suppresses the transition from IIDs to IDs in juvenile mouse hippocampus.
Animals
;
Animals, Newborn
;
Bicuculline
;
pharmacology
;
Disease Models, Animal
;
Epilepsy
;
pathology
;
GABA-A Receptor Agonists
;
pharmacology
;
GABA-A Receptor Antagonists
;
therapeutic use
;
Hippocampus
;
drug effects
;
metabolism
;
physiopathology
;
In Vitro Techniques
;
Magnesium
;
metabolism
;
pharmacology
;
Male
;
Membrane Potentials
;
drug effects
;
Mice
;
Mice, Inbred C57BL
;
Muscimol
;
pharmacology
;
Nerve Net
;
drug effects
;
Receptors, GABA-A
;
metabolism
7.Synthesis and activities of 4-(2-acetoxybenzoylamino) butyramide heterocyclic compounds.
Wen-Hu LIU ; Shi-Bao WANG ; Yi LIU
Acta Pharmaceutica Sinica 2012;47(11):1496-1502
It has been demonstrated by our previous research that 4-(2-acetoxybenzoylamino) butyramide derivatives exhibited good antiepileptic activities. In this paper, to explore the SAR and improve the antiepileptic activities of these derivatives, a series of novel 4-(2-acetoxybenzoylamino) butyramide heterocyclic compounds (5a-5n) were synthesized and biologically evaluated. Their structures were confirmed by 1H MNR, ESI-MS and elemental analysis. Pharmacological test in vivo showed that target compounds (5f, 5i-5n) displayed strong antiepileptic activities on 4-AP induced epilepsy in mice with ED50 values ranging from 0.3137 to 0.3604 mmol x kg(-1).
4-Aminopyridine
;
Amides
;
administration & dosage
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Animals
;
Anticonvulsants
;
administration & dosage
;
chemical synthesis
;
chemistry
;
therapeutic use
;
Dose-Response Relationship, Drug
;
Epilepsy
;
chemically induced
;
drug therapy
;
Female
;
Lethal Dose 50
;
Male
;
Mice
;
Molecular Structure
;
Random Allocation
;
Receptors, GABA
;
metabolism
;
Structure-Activity Relationship